Tokyo Tape
Sign in
← Tohoku Chemical

Quarterly report · Q1

7446.TEDINET S100Q8CO
Period2022-10-01 → 2022-12-31
Filed2023-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
MetricValuePeriodScopeSource row
Revenue¥9.4bn2022-10-01 → 2022-12-31Cons.Net sales
Revenue¥37.3bn2021-10-01 → 2022-09-30Cons.Net sales (5-year summary)
Revenue¥9.0bn2021-10-01 → 2021-12-31Cons.Net sales
Operating income¥254m2022-10-01 → 2022-12-31Cons.Operating income
Operating income¥214m2021-10-01 → 2021-12-31Cons.Operating income
Ordinary income¥271m2022-10-01 → 2022-12-31Cons.Ordinary income
Ordinary income¥1.0bn2021-10-01 → 2022-09-30Cons.Ordinary income loss (5-year summary)
Ordinary income¥229m2021-10-01 → 2021-12-31Cons.Ordinary income
Profit before tax¥271m2022-10-01 → 2022-12-31Cons.Income before income taxes
Profit before tax¥229m2021-10-01 → 2021-12-31Cons.Income before income taxes
Net income (owners)¥182m2022-10-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥658m2021-10-01 → 2022-09-30Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥148m2021-10-01 → 2021-12-31Cons.Profit loss attributable to owners of parent
Net income¥187m2022-10-01 → 2022-12-31Cons.Profit loss
Net income¥155m2021-10-01 → 2021-12-31Cons.Profit loss
Total assets¥19.2bnat 2022-12-31Cons.Assets
Total assets¥17.5bnat 2022-09-30Cons.Assets
Total assets¥18.1bnat 2021-12-31Cons.Total assets (5-year summary)
Total liabilities¥12.5bnat 2022-12-31Cons.Liabilities
Total liabilities¥10.8bnat 2022-09-30Cons.Liabilities
Net assets / equity¥6.7bnat 2022-12-31Cons.Net assets
Net assets / equity¥6.7bnat 2022-09-30Cons.Net assets
Net assets / equity¥6.3bnat 2021-12-31Cons.Net assets (5-year summary)
Cash and deposits¥2.4bnat 2022-12-31Cons.Cash and deposits
Cash and deposits¥1.4bnat 2022-09-30Cons.Cash and deposits
EPS (basic)¥202.312022-10-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥728.762021-10-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥163.692021-10-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
Equity ratio34.7%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio37.7%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio34.6%at 2021-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 20
SegmentItemPeriodValue
Otherother segmentsrevenue2022-10-01 → 2022-12-31¥17m
Otherother segmentsrevenue external2022-10-01 → 2022-12-31¥17m
jpcrp040300-q1r_E02810-000Foodreportable segmentrevenue2022-10-01 → 2022-12-31¥866m
jpcrp040300-q1r_E02810-000Foodreportable segmentrevenue external2022-10-01 → 2022-12-31¥866m
jpcrp040300-q1r_E02810-000Pharmaceutical Productsreportable segmentrevenue2022-10-01 → 2022-12-31¥4.6bn
jpcrp040300-q1r_E02810-000Pharmaceutical Productsreportable segmentrevenue external2022-10-01 → 2022-12-31¥4.6bn
jpcrp040300-q1r_E02810-000Reagent For Clinical Testreportable segmentrevenue2022-10-01 → 2022-12-31¥4.0bn
jpcrp040300-q1r_E02810-000Reagent For Clinical Testreportable segmentrevenue external2022-10-01 → 2022-12-31¥4.0bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-10-01 → 2022-12-31¥9.4bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-10-01 → 2022-12-31¥9.4bn
Otherother segmentsrevenue2021-10-01 → 2021-12-31¥20m
Otherother segmentsrevenue external2021-10-01 → 2021-12-31¥20m
jpcrp040300-q1r_E02810-000Foodreportable segmentrevenue2021-10-01 → 2021-12-31¥823m
jpcrp040300-q1r_E02810-000Foodreportable segmentrevenue external2021-10-01 → 2021-12-31¥823m
jpcrp040300-q1r_E02810-000Pharmaceutical Productsreportable segmentrevenue2021-10-01 → 2021-12-31¥4.4bn
jpcrp040300-q1r_E02810-000Pharmaceutical Productsreportable segmentrevenue external2021-10-01 → 2021-12-31¥4.4bn
jpcrp040300-q1r_E02810-000Reagent For Clinical Testreportable segmentrevenue2021-10-01 → 2021-12-31¥3.8bn
jpcrp040300-q1r_E02810-000Reagent For Clinical Testreportable segmentrevenue external2021-10-01 → 2021-12-31¥3.8bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-10-01 → 2021-12-31¥9.0bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-10-01 → 2021-12-31¥9.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 369
ItemContextValueUnit
Income taxes deferredPrior1YTDDuration15540000JPY
Income taxes deferredCurrentYTDDuration17470000JPY
Income taxesPrior1YTDDuration73871000JPY
Income taxesCurrentYTDDuration84861000JPY
Profit lossPrior1YTDDuration155059000JPY
Profit lossCurrentYTDDuration186547000JPY
Profit loss attributable to non controlling interestsPrior1YTDDuration6688000JPY
Profit loss attributable to non controlling interestsCurrentYTDDuration4263000JPY
Profit loss attributable to owners of parentPrior1YTDDuration148370000JPY
Profit loss attributable to owners of parentCurrentYTDDuration182284000JPY
Profit lossPrior1YTDDuration155059000JPY
Profit lossCurrentYTDDuration186547000JPY
Valuation difference on available for sale securities net of tax ociPrior1YTDDuration-1142000JPY
Valuation difference on available for sale securities net of tax ociCurrentYTDDuration-31694000JPY
Remeasurements of defined benefit plans net of tax ociPrior1YTDDuration-134000JPY
Remeasurements of defined benefit plans net of tax ociCurrentYTDDuration425000JPY
Other comprehensive incomePrior1YTDDuration-1277000JPY
Other comprehensive incomeCurrentYTDDuration-31268000JPY
Comprehensive incomePrior1YTDDuration153781000JPY
Comprehensive incomeCurrentYTDDuration155279000JPY
Comprehensive income attributable to owners of the parentPrior1YTDDuration147202000JPY
Comprehensive income attributable to owners of the parentCurrentYTDDuration151016000JPY
Comprehensive income attributable to non controlling interestsPrior1YTDDuration6579000JPY
Comprehensive income attributable to non controlling interestsCurrentYTDDuration4262000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q1r_E02810-000PharmaceuticalProductsReportableSegmentsMember4438315000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q1r_E02810-000ReagentForClinicalTestReportableSegmentsMember3761094000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q1r_E02810-000FoodReportableSegmentsMember822520000JPY
Revenues from external customersPrior1YTDDuration_OtherReportableSegmentsMember20394000JPY
Revenues from external customersPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember9042324000JPY
Revenues from external customersPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersPrior1YTDDuration9042324000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q1r_E02810-000PharmaceuticalProductsReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q1r_E02810-000ReagentForClinicalTestReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q1r_E02810-000FoodReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_OtherReportableSegmentsMember－JPY
Transactions with other segmentsPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember－JPY
Transactions with other segmentsPrior1YTDDuration_ReconcilingItemsMember－JPY
Transactions with other segmentsPrior1YTDDuration－JPY
Net salesPrior1YTDDuration_jpcrp040300-q1r_E02810-000PharmaceuticalProductsReportableSegmentsMember4438315000JPY
Net salesPrior1YTDDuration_jpcrp040300-q1r_E02810-000ReagentForClinicalTestReportableSegmentsMember3761094000JPY
Net salesPrior1YTDDuration_jpcrp040300-q1r_E02810-000FoodReportableSegmentsMember822520000JPY
Net salesPrior1YTDDuration_OtherReportableSegmentsMember20394000JPY
Net salesPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember9042324000JPY
Net salesPrior1YTDDuration_ReconcilingItemsMember－JPY
Net salesPrior1YTDDuration9042324000JPY
Gross profitPrior1YTDDuration_jpcrp040300-q1r_E02810-000PharmaceuticalProductsReportableSegmentsMember408331000JPY
Gross profitPrior1YTDDuration_jpcrp040300-q1r_E02810-000ReagentForClinicalTestReportableSegmentsMember355449000JPY
Gross profitPrior1YTDDuration_jpcrp040300-q1r_E02810-000FoodReportableSegmentsMember64564000JPY
Gross profitPrior1YTDDuration_OtherReportableSegmentsMember11496000JPY
Gross profitPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember839841000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-09-30pass
balance sheet identityconsolidated 2022-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-10-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-10-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-10-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-10-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass
statement vs summary · total assetsconsolidated 2022-12-31pass